# Long-Term Specified Drug Use-Results Survey for Xtandi Capsule

> **NCT02669771** · — · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 1018 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT02669771
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-30
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 1018 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669771, "Long-Term Specified Drug Use-Results Survey for Xtandi Capsule". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02669771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*